Investigation of the Effects of Omeprazole, a Proton Pump Inhibitor, on Apoptotic Gene Regions on Human Fibroblast Cells
Abstract
Proton pump is the first-line treatment for progression of stomach acids such as peptic ulcer disease, gastroesophageal reflux disease, and nonsteroidal anti-inflammatory drug-induced mucosal damage (Strand, Kim, and Peura 2017). Omeprazole, a proton pump inhibitor, is commonly used to treat gastroesophageal reflux disease, peptic ulcers, and other stomach conditions. OME inhibits H+/Na+ ATPase in the stomach view, ensuring proton secretion of the gastric lumen and reducing gastric acid secretion. Omeprazole's effect temperatures and support have not yet been defined in detail. In addition, prolonged duration of this situation brings with it some side effects (such as gastrointestinal diseases, bone fractures, vitamin and mineral deficiencies) (Fontecha-Barriuso et al. 2020). Therefore, it is of great importance to elucidate the complement in detail for the effectiveness of this transaction process. In our expansion study in this direction, the effectiveness of this pressure on cell viability on fibroblast conditions where Omeprazole was applied in various regions was determined by viability test, while the effectiveness on the expression disruption of apoptotic genes with this pressure was carried out by quantitative real-time PCR analyses. It is aimed to use the additive to better preserve the obtained results of Omeprazole with the data obtained from the analysis results.
Keywords
Omeprazole, Proton pump inhibitors, Apoptosis, Cell Viability
References
- 1. Atkins, Ashton, ve Chandra Sekar. 2013. “Proton Pump Inhibitors: Their Misuse, Overuse, And Abuse”. IOSR Journal of Pharmacy 3. doi:10.9790/3013-32202529.
- 2. Calleja, Luis Francisco, Belem Yoval-Sánchez, Luz Hernández-Esquivel, Juan Carlos Gallardo-Pérez, Marcela Sosa-Garrocho, Álvaro Marín-Hernández, Ricardo Jasso-Chávez, Marina Macías-Silva, ve José Salud Rodríguez-Zavala. 2021. “Activation of ALDH1A1 by Omeprazole Reduces Cell Oxidative Stress Damage”. The FEBS Journal 288(13): 4064-80. doi:10.1111/febs.15698.
- 3. Der, Gabriella. 2003. “An Overview of Proton Pump Inhibitors”. Gastroenterology Nursing: The Official Journal of the Society of Gastroenterology Nurses and Associates 26(5): 182-90. doi:10.1097/00001610-200309000-00003.
- 4. Fontecha-Barriuso, Miguel, Diego Martín-Sanchez, Julio M. Martinez-Moreno, Daniela Cardenas-Villacres, Susana Carrasco, Maria D. Sanchez-Niño, Marta Ruiz-Ortega, Alberto Ortiz, ve Ana B. Sanz. 2020. “Molecular pathways driving omeprazole nephrotoxicity”. Redox Biology 32: 101464. doi:10.1016/j.redox.2020.101464.
- 5. Hou, Yichao, Qiang Hu, Jiao Huang, ve Hua Xiong. 2018. “Omeprazole Inhibits Cell Proliferation and Induces G0/G1 Cell Cycle Arrest through Up-regulating miR-203a-3p Expression in Barrett’s Esophagus Cells”. Frontiers in Pharmacology 8: 968. doi:10.3389/fphar.2017.00968.
- 6. Murali, Shreya, ve Randall Reif. 2023. “Apoptosis Induction in Jurkat T-Lymphocytes by Proton Pump Inhibitors (PPIs)”. Student Research Submissions. https://scholar.umw.edu/student_research/526.
- 7. “Omeprazole Induces Apoptosis in Normal Human Polymorphonuclear Leucocytes - E. Capodicasa, P. Cornacchione, B. Natalini, A. Bartoli, S. Coaccioli, P. Marconi, L. Scaringi, 2008”. https://journals.sagepub.com/doi/abs/10.1177/039463200802100109 (20 Nisan 2024).
- 8. Strand, Daniel S., Daejin Kim, ve David A. Peura. 2017. “25 Years of Proton Pump Inhibitors: A Comprehensive Review”. Gut and Liver 11(1): 27-37. doi:10.5009/gnl15502.
- 9. Sun, Qing-Hua, Hong-Yan Wang, Shi-Dong Sun, Xin Zhang, ve Han Zhang. 2019. “Beneficial Effect of Probiotics Supplements in Reflux Esophagitis Treated with Esomeprazole: A Randomized Controlled Trial”. World Journal of Gastroenterology 25(17): 2110-21. doi:10.3748/wjg.v25.i17.2110.
- 10. Walt, R P, M D Gomes, E C Wood, L H Logan, ve R E Pounder. 1983. “Effect of daily oral omeprazole on 24 hour intragastric acidity.” British Medical Journal (Clinical research ed.) 287(6384): 12-14.